Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 236 | 107 | 128 |
| Samples | 218 | 93 | 124 |
| Peptides | 111 | 26 | 91 |
Function
YBX1 · Y-box binding protein 1
This gene encodes a highly conserved cold shock domain protein that has broad nucleic acid binding properties. The encoded protein functions as both a DNA and RNA binding protein and has been implicated in numerous cellular processes including regulation of transcription and translation, pre-mRNA splicing, DNA reparation and mRNA packaging. This protein is also a component of messenger ribonucleoprotein (mRNP) complexes and may have a role in microRNA processing. This protein can be secreted through non-classical pathways and functions as an extracellular mitogen. Aberrant expression of the gene is associated with cancer proliferation in numerous tissues. This gene may be a prognostic marker for poor outcome and drug resistance in certain cancers. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on multiple chromosomes. [provided by RefSeq, Sep 2015].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000321358 | P67809 | 236 | 111 |
Gene Properties
Recurrent Mutations
All 111 amino-acid changes on canonical ENST00000321358 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in YBX1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in YBX1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 9/612 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 7/1390 0% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 10/2550 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 10/1592 1% |
| Melanoma | 0/210 0% | 14/1899 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Ovarian Carcinoma | 4/109 4% | 3/998 0% |
| Pancreatic Carcinoma | 5/89 6% | 5/1611 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Hepatocellular Carcinoma | 2/46 4% | 10/2210 0% |
| Gastric Carcinoma | 4/74 5% | 6/1809 0% |
| Colorectal Carcinoma | 7/143 5% | 10/3239 0% |
| Other Solid Cancers | 2/94 2% | 6/1515 0% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Bladder Carcinoma | 1/58 2% | 2/956 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Glioma | 2/52 4% | 4/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Breast Carcinoma | 4/144 3% | 5/3264 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 1/752 0% |
Mutation Distribution
Where YBX1 is mutated · all tissues, split by cell line vs tissue
How many mutations in YBX1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 236 mutations in YBX1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|